CRP and myocardial infarction: The ongoing Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) is just testing whether reducing inflammation among men and women who have had a prior heart attack and have CRP > 2 ngm/ml can reduce the risk of another cardiovascular event happening in the future.